CD274 and non-small cell lung carcinoma: PD‐L1 <1% expression was reported in 55.6% of patients enrolled on ADIPemCis, a prevalence that is significantly higher than that reported across key studies of pembrolizumab in NSCLC (33%), but consistent with real‐world data (48%–56.4%).27, 28, 29